News
CMS Encouraged to Revise Reimbursement, Payment Policies for Biosimilars
The Centers for Medicare and Medicaid Services are being urged to make changes that could improve savings for patients and health care payers, as well as expand patient access to biosimilars. READ MORE

From The Journal

Rationale for the Development of Clinical Pathways and an Overview of the Clinical Pathways Office at the Seattle Cancer Care Alliance
Sanu Jain, BS, MHA
This paper examines the establishment of the Seattle Cancer Care Alliance Clinical Pathways Office, as well as the goals of clinical pathway development from the standpoint of a regional hospital system. READ MORE
ESMO 2017 Congress

Conferences

ESMO 2017 Congress
September 8-12 marked the annual European Society for Medical Oncology (ESMO) Congress. Cancer researchers and clinicians came together in Madrid, Spain to enable collaboration and the exchange of important ideas in oncology. Journal of Clinical Pathways has provided some of the most relevant discussions from the congress. READ MORE

Interviews

Financial Navigators to Address Cancer Cost Concerns
JCP Editors
Journal of Clinical Pathways spoke with Jennifer Singleterry, MA about the role of financial navigators in the oncology landscape and strategies for greater global insurance literary across the spectrum. READ MORE

Pharma Insights

Are Formulary Exclusion Lists Aligned or Contrary to the Shift to Value-Base Care?
Andrew Cournoyer, RPh, MBA; Larry Blandford, PharmD—Column Editor
Annual updates to formulary exclusion lists suggest a need for careful evaluation by benefit sponsors, clinicians, patient advocacy groups, and the pharmaceutical industry to determine implications on treatment outcomes and achieving value-based care. READ MORE